Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) R&D In Process (2018 - 2024)

Avalo Therapeutics filings provide 3 years of R&D In Process readings, the most recent being $103000.0 for Q2 2024.

  • On a quarterly basis, R&D In Process changed N/A to $103000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was $103000.0, a 99.63% decrease, with the full-year FY2024 number at $27.6 million, changed N/A from a year prior.
  • R&D In Process hit $103000.0 in Q2 2024 for Avalo Therapeutics, down from $27.5 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $27.5 million in Q1 2024 to a low of $103000.0 in Q2 2024.